The Maxillofacial Center for Diagnostics & Research

The Book of Maxillofacial Lists

Tables 5: Epidemiology of Erythroplakia & Carcinoma in situ


The following lists and tables of data have been compiled in the hopes that it will be useful to those seeking information pertaining to diseases of the oral and maxillofacial region. We have tried to be as accurate as possible, but you are responsible for proper use of the information. References to the source of the data can be found by clicking on the "References" button associated with the table.  


Incidence of Oral Carcinoma in situ

Table 5a: Malignant transformation rates (%) of the largest leukoplakia follow-up studies from Europe and the United States, ranked by sample size (modified from Bouquot JE, Whitaker SB. Quint Internat 1994; 25:133-140).

Author(s)

Country # Pts. Cumulative Years of Follow-up Malignant
Transformation
Potential
Annual
Cancer
Rate
Einhorn, Wersall (1967) Sweden 782

9,149 p-y (mean: 11.7yrs)

4.0% 0.34%
Banoczy (1977) Hungary 670

6,566 p-y (mean: 9.8 yrs)

6.0 0.61
Bouquot, et al (1988) * U.S.A. 463

6,720 p-y (mean: 11.8 yrs)

10.3 0.82
Roed-Peterson (1971) Denmark 331

1,423 p-y (mean: 4.3 yrs)

3.6 0.82
Leonardelli, Talamazzi (1950) Italy 268

1,340 p-y (mean: n/a)

19.8 0.40
Silverman et al (1984) U.S.A. 257

1,850 p-y (mean: n/a)

17.5 0.24
Pindborg, et al (1968) Denmark 248

918 p-y (mean: 3.7 yrs.)

4.4 1.20
Maerker, Burkhardt (1978) Germany 200

1,000 p-y (mean: 5.0 yrs)

12.0 2.40
Kramer, et al (1970) England 187

935 p-y (mean: n/a)

4.8 0.96
Sturgis, Lund (1934) U.S.A. 143

715 p-y (mean: 5.0 yrs)

13.0 2.37
Total 3,549

30,616 person-years

8.1% **1.07%

        * includes 13 cases from the pharynx.
       ** weighed for different sample sizes; many studies include a disproportional sampling of high risk lesions;              the overall malignant
             transformation rate is usually considered to be 4-6% when all lesions are assessed.